The broader goals of the current studies were to(1) provide further in vivo evidence of an interaction between tauopathy and cholinergic atrophy in tau transgenic L1 mice, (2) test whether HMTM administration attenuates the development of tauopathy and worsening of the cholinergic status in an animal AD model and (3) provide a better insight into the decreased therapeutic efficacy when HMTM is administered against the background of a symptomatic rivastigmine treatment. The gene discussed is MAPT; the disease is tauopathy.